Arcturus Therapeutics Holdings Inc. Common Stock (ARCT) is a publicly traded Healthcare sector company. As of May 21, 2026, ARCT trades at $6.95 with a market cap of $199.81M and a P/E ratio of -2.40. ARCT moved +1.94% today. Year to date, ARCT is +7.06%; over the trailing twelve months it is -46.30%. Its 52-week range spans $5.85 to $25.88. Analyst consensus is buy with an average price target of $18.50. Rallies surfaces ARCT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Arcturus Extends Cash Runway to Q2 2028, Initiates 12-Week CF Study with 10mg Dose: Arcturus extended its cash runway into the second quarter of 2028, reflecting robust financial management. The company plans a 12-week Phase 2 trial of ARCT-032 at a 10mg dose in cystic fibrosis patients, incorporating lung clearance index, high-resolution CT, spirometric stability criteria and quality-of-life endpoints.
| Metric | Value |
|---|---|
| Price | $6.95 |
| Market Cap | $199.81M |
| P/E Ratio | -2.40 |
| EPS | $-2.83 |
| Dividend Yield | 0.00% |
| 52-Week High | $25.88 |
| 52-Week Low | $5.85 |
| Volume | 202 |
| Avg Volume | 0 |
| Revenue (TTM) | $54.71M |
| Net Income | $-78.67M |
| Gross Margin | 0.00% |
10 analysts cover ARCT: 0 strong buy, 7 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $18.50.